Results 141 to 150 of about 17,238,138 (390)

Defining Roles in Pediatric Palliative Care: Perspectives From Oncology and Palliative Care Teams

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Early integration of pediatric palliative care (PPC) is associated with improved symptom management, quality of life, and healthcare utilization for children with cancer. Despite this, variation persists in how PPC is understood, operationalized, and integrated within pediatric oncology programs. In particular, ambiguity surrounding
Leeat Granek   +13 more
wiley   +1 more source

The noni anthraquinone damnacanthal is a multi-kinase inhibitor with potent anti-angiogenic effects [PDF]

open access: yes, 2017
Este es el manuscrito que fue aceptado y que finalmente se publicó en Cancer Letters con el DOI: 10.1016/j.canlet.2016.10.037The natural bioactive compound damnacanthal inhibits several tyrosine kinases.
García-Vilas, Javier A.   +4 more
core  

Feasibility and Preliminary Efficacy of Integrative Neuromuscular Training for Childhood Cancer Survivors: A Pilot Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivors of childhood acute lymphoblastic leukemia (ALL) often exhibit early deficits in muscle and movement competence, which can compromise long‐term health. Integrative neuromuscular training (INT), a multifaceted approach combining fundamental movement activities with strength exercises, may help address these deficits during ...
Anna Maria Markarian   +7 more
wiley   +1 more source

Ovarian Cancer [PDF]

open access: yesCA: A Cancer Journal for Clinicians, 1986
Early diagnosis is the most effective means of reducing the currently high mortality rate associated with ovarian cancer. The palpation of what appears to be a normal size ovary in a premenopausal woman suggests an ovarian tumor in a postmenopausal woman.
openaire   +4 more sources

Two Faces of NOTCH1 in Childhood Lymphoblastic T‐Cell Neoplasia: Prognostic Divergence of Mutational and Structural Aberrations

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT In pediatric patients, T‐cell lymphoblastic lymphoma (T‐LBL) survival exceeds 80%. Relapse remains associated with limited curative options. Frontline treatment is largely extrapolated from T‐cell acute lymphoblastic leukemia (T‐ALL) treatment, reflecting the ongoing debate, whether both entities represent distinct diseases or variants within ...
Marie C. Heider   +4 more
wiley   +1 more source

Cancer [PDF]

open access: yesJournal of Investigative Dermatology, 2015
R R, Butrum, M J, Messina
openaire   +4 more sources

The role and potential of community based cancer care for Māori in Aotearoa/New Zealand : A thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Public Health at Massey University, Wellington, New Zealand [PDF]

open access: yes, 2016
There are unacceptable ethnic differences in cancer survival in Aotearoa/New Zealand and quality of life differs between Māori and non-Māori at all stages of the cancer journey. Overseas studies have recognised that all the priorities for cancer services
Slater, Tania Michelle
core  

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman   +7 more
wiley   +1 more source

Ovarian cancer [PDF]

open access: yesSeminars in Surgical Oncology, 1987
AbstractEven though cisplatin‐based combination chemotherapy results in increased clinical and surgical complete remission rates and improved median survival compared with single‐agent alkylating agent chemotherapy, the 5 year survival rates for stages III and IV ovarian cancer have only improved to 25–30%.
openaire   +3 more sources

Home - About - Disclaimer - Privacy